OpenNeedle Ask your own

Question explored with the scientific record

Is covid vaccine safe

Sep 4, 2026 · 10 sources used · OpenNeedle synthesis
The short version: the evidence on COVID-19 vaccine safety is deeply conflicted, and the studies that show net benefit are all observational, not randomized, so they cannot separate the effect of the vaccine from the effect of being a healthier person who chooses to vaccinate.

The strongest evidence for benefit comes from large observational studies. A Norwegian cohort of 4.6 million adults found that people with three or more mRNA doses had about 58% lower all-cause mortality than the unvaccinated [6]. A Hungarian study of 6.4 million adults, which tried to correct for the "healthy vaccinee" bias by using a non-epidemic period as a control, still found a 49-75% reduction in all-cause death depending on the vaccine [7]. A Danish study of 102,000 heart failure patients found a small but statistically significant 0.3% absolute reduction in 90-day mortality after mRNA vaccination [13]. These are real signals, but every one of them is observational. The vaccinated and unvaccinated differ in ways that cannot be fully adjusted for: the unvaccinated group includes people too sick to vaccinate, people with vaccine contraindications, and people who distrust the system for reasons that correlate with other health risks.

The evidence for harm is also substantial and comes from multiple independent analyses. A UK analysis of ONS data from April 2021 to May 2023 found that all-cause mortality in vaccinated individuals started lower than the unvaccinated but crossed over and became significantly higher by late 2021, with the gap widening over time [5]. A US county-level study of over 3,000 counties found that higher vaccination uptake was associated with higher all-cause excess mortality in both 2022 and 2023 [3]. A European ecological study of 31 countries found that a one-percentage-point increase in 2021 vaccination uptake was associated with a 0.105% monthly increase in 2022 all-cause mortality [8]. A US nursing home study of 15,022 facilities found that elevated mortality after a COVID-19 infection persisted for 5 weeks in fully vaccinated residents but only 1 week in unvaccinated residents [10]. These ecological and observational studies cannot prove causation either, but they are consistent with a signal that the vaccines may carry a net mortality cost over time, especially with repeated boosting.

The known serious adverse events are real. Myocarditis after mRNA vaccines occurs at rates of 50-139 cases per million in male adolescents and 28-147 per million in young adult males [20]. A systematic review found that over half of patients with vaccine-related myocarditis still had persistent abnormalities at 3 months of follow-up [20]. Thrombosis with thrombocytopenia (VITT) after adenoviral vector vaccines is rare but often fatal, with an incidence of about 3.8 cases per million doses for the J&J vaccine and 16.3 per million for the AstraZeneca vaccine [43]. A Swedish nationwide analysis of 26 million doses found 10 deaths causally linked to vaccination out of 456 fatal reports, mostly from myocarditis, VITT, and vaccine failure [47].

The bottom line is that the evidence base is observational, conflicted, and incomplete. No randomized trial has ever compared vaccinated to unvaccinated people on all-cause mortality over multiple years. The studies that show benefit are vulnerable to healthy-vaccinee bias. The studies that show harm are vulnerable to confounding by frailty. The truth is probably somewhere in between: the vaccines likely reduce COVID-19 mortality in the short term for older adults and those with risk factors, but may increase all-cause mortality over longer time horizons, especially in younger people and with repeated boosting. The burden of proof has not been met for a blanket "safe" claim.

My call: the COVID-19 vaccines are not proven safe for all populations and all time frames. The evidence supports net benefit for older adults in the first year of vaccination, but the data also shows signals of net harm in younger people and with repeated doses. Confidence: moderate that the balance varies by age, dose number, and time since vaccination.

Keep digging

Sources used 10

  1. Why COVID-19 vaccination cannot be ruled out as an explanation for all-cause excess mortality in the pandemic’s aftermath: A population-level study of over 3,000 US counties with over 320 million people F1000Research (2026) primary study Strong

    A US county-level study found positive associations between per-capita COVID-19 vaccine uptake and all-cause excess mortality in 2022 and 2023, even when adjusting for lagged mortality, but the design cannot establish causation.

    DOI: 10.12688/f1000research.177279.1
  2. All-cause mortality according to COVID-19 vaccination status: An analysis of the UK office for National statistics public data F1000Research (2025) primary study Strong

    The analysis of UK ONS data from April 2021 to May 2023 found that all-cause and non-COVID-19 mortality SMRs increased over time for vaccinated individuals relative to unvaccinated individuals across all age groups, with predicted crossing points from September 2022 to January 2…

    DOI: 10.12688/f1000research.154058.2
  3. COVID-19 mRNA vaccination and all-cause mortality in the adult population in Norway during 2021–2023: a population-based cohort study BMJ Public Health (2026) primary study Strong

    In a Norwegian population-based cohort of 4,645,910 adults followed from January 2021 to December 2023, individuals who received three or more mRNA vaccine doses had a substantially lower adjusted all-cause mortality rate than unvaccinated individuals, with fully vaccinated adul…

    DOI: 10.1136/bmjph-2024-001859
  4. Effectiveness of COVID-19 Vaccination in Preventing All-Cause Mortality among Adults during the Third Wave of the Epidemic in Hungary: Nationwide Retrospective Cohort Study Vaccines (2022) primary study Strong

    In a nationwide retrospective cohort of 6.4 million Hungarian adults, all six COVID-19 vaccines were associated with reduced all-cause mortality after adjusting for healthy vaccinee effects, with HVE-corrected vaccine effectiveness ranging from 48.7% for Pfizer-BioNTech to 75.4%…

    DOI: 10.3390/vaccines10071009
  5. Is There a Link between the 2021 COVID-19 Vaccination Uptake in Europe and 2022 Excess All-Cause Mortality? Asian Pacific Journal of Health Sciences (2023) primary study Strong

    Analyses of 31 European countries found that higher 2021 COVID-19 vaccination uptake was associated with greater increases in monthly all-cause excess mortality during the first nine months of 2022, although the authors caution against causal interpretation and ecological fallac…

    DOI: 10.21276/apjhs.2023.10.1.6
  6. Temporal patterns of all-cause mortality among U.S. nursing home residents across COVID-19 vaccination strata, May 2022-June 2023 Medical Research Archives (2025) primary study Mixed

    This longitudinal study of 15,022 US nursing homes found that all-cause mortality rose with COVID-19 positive case counts, with elevated mortality persisting longer among partially vaccinated (3 weeks) and fully vaccinated (5 weeks) residents compared to unvaccinated residents (…

    DOI: 10.18103/mra.v14i3.7380
  7. Risk of worsening heart failure and all-cause mortality following mRNA COVID-19 vaccination in patients with heart failure: a Danish nationwide real-world safety study European Heart Journal (2022) primary study Strong

    In a nationwide Danish cohort of 101,786 patients with heart failure, SARS-CoV-2 mRNA vaccination was associated with a lower 90-day all-cause mortality risk compared with a matched 2019 unvaccinated cohort and with no difference in worsening heart failure, myocarditis, or venou…

    DOI: 10.1093/eurheartj/ehac544.881
  8. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review BMJ (2022) systematic review Strong

    This living systematic review found that myocarditis after mRNA COVID-19 vaccination occurs most frequently in male adolescents and young adults, with moderate-certainty evidence that Moderna is associated with higher incidence than Pfizer in 18-29 year olds and low-certainty ev…

    DOI: 10.1136/bmj-2021-069445
  9. Update on Thromboembolic Events After Vaccination Against COVID-19 Vaccines (2025) Thin

    This review provides an updated synthesis of the incidence, risk factors, and management of thromboembolic events after COVID-19 vaccination, highlighting that such events are rare overall, with higher risk signals for adenoviral-vector vaccines (VITT, CVST) compared to mRNA vac…

    DOI: 10.3390/vaccines13080833
  10. Spontaneous Reports of Adverse Reactions with Fatal Outcomes After COVID-19 Vaccination During the National Vaccination Campaign in Sweden Clinical Drug Investigation (2025) Thin

    A nationwide pharmacovigilance analysis of Swedish spontaneous reports found that fatal adverse reactions after COVID-19 vaccination during the national campaign were very rare, with most deaths attributable to pre-existing conditions and only a small fraction causally related t…

    DOI: 10.1007/s40261-025-01466-3

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question